Caption Management’s BridgeBio Pharma BBIO Stock Holding History

Caption Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32K	Buy	+431	New	+$31.2K	﹤0.01%	1440
2025 Q1	–	Sell	-21,900	Closed	-$738K	–	1519
2024 Q4	$601K	Sell	21,900 -38,100	-64%	-$985K	0.01%	1050
2024 Q3	$1.53M	Sell	60,000 -346,000	-85%	-$9.08M	0.02%	653
2024 Q2	$10.3M	Buy	406,000 +95,566	+31%	+$2.61M	0.16%	136
2024 Q1	$9.6M	Buy	+310,434	New	+$10.6M	0.15%	178
2023 Q4	–	Sell	-90,600	Closed	-$2.72M	–	1340
2023 Q3	$2.39M	Buy	+90,600	New	+$2.57M	0.04%	532
2023 Q2	–	Sell	-46,817	Closed	-$704K	–	1103
2023 Q1	$776K	Buy	+46,817	New	+$546K	0.02%	684
2022 Q2	–	Sell	-20,000	Closed	-$167K	–	1453
2022 Q1	$203K	Sell	20,000 -164,651	-89%	-$1.69M	﹤0.01%	1271
2021 Q4	$3.08M	Buy	+184,651	New	+$7.81M	0.03%	631

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's BBIO Position: Q1 2026 in Review

Caption Management opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 431 shares worth $32K. The stake represents ﹤0.01% of the portfolio and ranks #1440 among its holdings. This is a return to the name: Caption Management previously reported a position in BBIO as recently as Q4 2024.

Caption Management first reported a position in BBIO in Q4 2021 and has held it in 9 quarters since. The position peaked at $10.3M in Q2 2024. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Caption Management held 431 shares of BridgeBio Pharma worth $32K as of Q1 2026.
BridgeBio Pharma was a new Caption Management position in Q1 2026.
BridgeBio Pharma made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1440 holding.
Caption Management first reported a position in BridgeBio Pharma in Q4 2021 and has held it in 9 quarters since.
Caption Management's BridgeBio Pharma position peaked at $10.3M in Q2 2024.
458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.